Fortune 40: Stock picks to retire on

Forty stock picks inspired by the greatest investors of all-time: From the deepest values to solid growth, these shares can make retirement dreams come true.

NVS: The numbers
Market Cap $144.1 billion
Total Return YTD (June 11) -2.4%
Total Return Last 12 Months 4.3%
Earnings Growth (Next Five Years) 13.0%
P/E (Pasts 12 months) 17.5
P/E (Next Year's Estimate) 14.4
Dividend Yield 2.0%
Source: Baseline, as of June 11, 2007.
Foreign Value
A strong pipeline and top-notch generics portfolio make the Swiss drug maker an industry leader. Unlike many other drug giants and biotechs, Novartis has spread its bets across three areas of business - pharmaceuticals, generics and biotechs - that typically fight tooth and nail.

If the pharma industry takes a dive, the company can rely on generics in tough times. If generics slow down, Novartis can fall back on pharma.

The company also maintains partnerships with Genentech, the world's No. 2 biotech. And it produces vaccines, a traditionally slow industry that is now producing blockbusters.
Abbott Labs Johnson & Johnson Coca-Cola Altria Group Colgate General Mills Procter & Gamble Wyeth Accenture AIG Chubb ConocoPhillips McKesson 3M Microsoft United Health Pfizer Aetna Applied Industrial Carpenter Technology Loews Lufkin Tidewater VF Corp. Grey Wolf CSG Systems Hercules K-Swiss Navigant Consulting Park Electrochemical Penn Virginia Plexus UBS Diageo Novartis Petroleo Brasileiro Sanofi-Aventis Total Unilever Vodafone
Bargain hunting for condos The real estate slowdown has made parts of the Sunbelt a lot more affordable. Fortune presents a guide to finding the best deals in five markets. (more)
Retired at 50 Is it possible for someone who doesn't run a hedge fund or win the lottery to retire at 50 (or so)? Yes. (more)
Retirement: Now what?! Think you know what will make you happy? Learn from those who've been there, done that. (more)